Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Thyroid Cancer Treatment Market : By Treatment Type, By Drugs, By Distribution Channel and Region Forecast 2020-2031
Thyroid Cancer Treatment Market : By Treatment Type, By Drugs, By Distribution Channel and Region Forecast 2020-2031
Thyroid Cancer Treatment Market size was valued at US$ 1,757.4 million in 2024 and is expected to reach US$ 2,489.3 million by 2031, growing at a significant CAGR of 5.1% from 2025-2031. The global market provides a detailed overview and which can be segmented by treatment type, drugs, distribution channel, and region. By treatment type, the market has been segmented into iodine therapy, thyroxin treatment, and chemotherapy (cisplatin, doxorubicin)). By treatment type, the chemotherapy segment held the majority of the revenue share of the market in the historic period and is anticipated to have led the segment growth rate over the forecasted period due to an increase in the demand for chemotherapy in various types of cancer. By drugs, the market has been segmented into levothyroxine and radioiodine.
By drugs, the radioiodine segment held the largest revenue share of the market in these current years and is expected to have the fastest growth rate over the forecasted period. By distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and others. By treatment type, the chemotherapy segment held the largest revenue share of the gastric cancer therapy market in past years and is expected to have the fastest growth rate over the forecasted period due to a high prescription rate.
Study Period
2025-2031Base Year
2024CAGR
5.1%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The increasing prevalence of thyroid cancer globally, along with the rising investment in healthcare expenditure are the primary driver for the growth of the thyroid cancer treatment market. Furthermore, the increasing geriatric population and the growing middle-class population in emerging economies are on a global level further expected to fuel the market in current years. For instance, as per the data collected from the United Nations Department of Economic and Social Affairs, in 2020, the estimated elderly population aged above 65 accounted for 727 million and by 2050 the number is projected to get double nearly to 1,500 million.
North America is estimated to occupy the largest share of the global thyroid cancer treatment market in terms of revenue, owing to the rising healthcare investment, accompanied by the presence of leading healthcare service providers, and the growing number of cancer patients in the region. Apart from this, the countries in North America such as the United States are encouraging cancer care for cancer patients, which is further anticipated to contribute to the market growth in the region. As per the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were reported in the United States. This increased rate of cancer is further expected to fuel the demand for thyroid cancer treatment products in North American countries.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 1,757.4 million |
|
Market Size in 2031 |
US$ 2,489.3 million |
|
Market CAGR |
5.1% |
|
By Treatment Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The thyroid cancer treatment market size was valued at US$ 1,757.4 million in 2024 and is expected to reach US$ 2,489.3 million by 2031, growing at a significant CAGR of 5.1% from 2025-2031
North America is estimated to have the largest share of the market.
The key players are: Abbott Laboratories Hoffmann-La Roche Ltd. Thermo Fisher Scientific Inc., Siemens AG Bio Rad Laboratories Inc. GE Healthcare, Illumina, Inc. Koninklijke Philips N.V. Toshiba Medical Systems Corporation
| 1. Executive Summary |
| 2. Global Thyroid Cancer Treatment Market Introduction |
| 2.1.Global Thyroid Cancer Treatment Market - Taxonomy |
| 2.2.Global Thyroid Cancer Treatment Market - Definitions |
| 2.2.1.Treatment Type |
| 2.2.2.Drugs |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Thyroid Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Thyroid Cancer Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Thyroid Cancer Treatment Market By Treatment Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Iodine Therapy |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Thyroxin Treatment |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Chemotherapy |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Cisplatin |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Doxorubicin |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Thyroid Cancer Treatment Market By Drugs, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Levothyroxine |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Radioiodine |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Thyroid Cancer Treatment Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Thyroid Cancer Treatment Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Iodine Therapy |
| 9.1.2.Thyroxin Treatment |
| 9.1.3.Chemotherapy |
| 9.1.4.Cisplatin |
| 9.1.5.Doxorubicin |
| 9.2. Drugs Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Levothyroxine |
| 9.2.2.Radioiodine |
| 9.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Iodine Therapy |
| 10.1.2.Thyroxin Treatment |
| 10.1.3.Chemotherapy |
| 10.1.4.Cisplatin |
| 10.1.5.Doxorubicin |
| 10.2. Drugs Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Levothyroxine |
| 10.2.2.Radioiodine |
| 10.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Iodine Therapy |
| 11.1.2.Thyroxin Treatment |
| 11.1.3.Chemotherapy |
| 11.1.4.Cisplatin |
| 11.1.5.Doxorubicin |
| 11.2. Drugs Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Levothyroxine |
| 11.2.2.Radioiodine |
| 11.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Iodine Therapy |
| 12.1.2.Thyroxin Treatment |
| 12.1.3.Chemotherapy |
| 12.1.4.Cisplatin |
| 12.1.5.Doxorubicin |
| 12.2. Drugs Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Levothyroxine |
| 12.2.2.Radioiodine |
| 12.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Iodine Therapy |
| 13.1.2.Thyroxin Treatment |
| 13.1.3.Chemotherapy |
| 13.1.4.Cisplatin |
| 13.1.5.Doxorubicin |
| 13.2. Drugs Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Levothyroxine |
| 13.2.2.Radioiodine |
| 13.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Abbott Laboratories |
| 14.2.2.Hoffmann-La Roche Ltd. |
| 14.2.3.Thermo Fisher Scientific Inc., |
| 14.2.4.Siemens AG |
| 14.2.5.Bio Rad Laboratories Inc. |
| 14.2.6.GE Healthcare, |
| 14.2.7.Illumina, Inc. |
| 14.2.8.Koninklijke Philips N.V. |
| 14.2.9.Toshiba Medical Systems Corporation |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.